European Active Surveillance of Renal Cell Carcinoma Study

niversity of Eastern Piedmont Department of Translational Medicine0 个研究点目标入组 400 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•oMales or females, age = 18 years.
•oIncidental diagnosis at imaging (ultrasonography, CT, MRI) of a solid renal mass < 4 cm in maximum diameter (pT1a).
•oHistologically confirmed RCC by percutaneous needle biopsy at diagnosis. All RCC subtypes are eligible for the study.
•oPatients unfit for active treatment due to advanced age, or co-morbidity, or choosing to avoid active treatment.
•oSigned Informed consent.
•oPreparedness to comply with percutaneous tumor biopsy and a close follow-up protocol

•oRenal tumors with a non-RCC histology (sarcomas, lymphomas, etc.).
•oPresence of metastatic disease at diagnosis
•oTumor related symptoms at presentation.
•oPatients with known genetic diseases associated with RCC (VHL, BHD, HLRCC, etc.).
•oPatients unsuitable for biopsy due to need for concomitant anticoagulation or anti-platelet drug use which cannot be transiently discontinued.
•oPatients unsuitable for biopsy due to tumor location or small tumor size.
•oPatients with concurrent systemic treatment for another cancer.
•oPatients with estimated life expectancy < 1 year.

发起方

niversity of Eastern Piedmont Department of Translational Medicine